Anti-inflammatory Effects of Simvastatin

• Status: Active, not recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine which of the two ingredients of Vytorin (Simvastatin or Ezetimibe) is responsible for the anti-inflammatory effects of Vytorin

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Paresh Dandona
• Treatments: Ezetimibe; Simvastatin

Criteria

Inclusion Criteria:

1. Age: 18 to 75 years of age.

2. Obese (BMI ≥30 kg/m2)

3. LDL cholesterol of ≥100 mg/dl

4. Not taking any vitamins or antioxidants

Exclusion Criteria:

1. Currently using anti-hyperlipidemic therapies

2. Triglycerides >500 mg/dl.

3. Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months.

4. Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids

5. Hepatic disease

6. Renal impairment.

7. History of drug or alcohol abuse

8. Participation in any other concurrent clinical trial

9. Use of an investigational agent or therapeutic regimen within 30 days of study.

10. Smoker

11. Pregnancy

12. Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation

13. Anemia with hemoglobin <12 g/dl